Smith M A, Smith J G
Centre for Research in Biomedicine, Faculty of Applied Sciences, University of the West of England, Bristol, UK.
Clin Lab Haematol. 2002 Apr;24(2):93-7. doi: 10.1046/j.1365-2257.2002.00431.x.
This paper outlines the impact of granulocyte-colony stimulating factor (G-CSF) used as a single modality therapy in 17 patients with secondary autoimmune neutropenia (S-AIN) who had been treated a multiple number of times previously. Fifteen of these patients had demonstrable antineutrophil antibodies and two had cellular S-AIN with haemopoietic inhibitory T-cells present in the marrow. Prior to treatment, all had had problems with infection. All patients responded within 7 days of commencement of treatment. Provided G-CSF neutrophil counts were maintained above 1 x 109/l, no further infections occurred. This was achievable by using G-CSF administered as infrequently as once every 8 days. Eight of the 17 patients remained on G-CSF, although five switched to the glycosylated form because of side-effects. None have developed osteoporosis despite 47.29 patient years of total experience with G-CSF. In conclusion both glycosylated and nonglycosylated G-CSF can be used effectively in treating AIN on a long-term basis.
本文概述了粒细胞集落刺激因子（G-CSF）作为单一疗法用于17例既往接受过多次治疗的继发性自身免疫性中性粒细胞减少症（S-AIN）患者的疗效。其中15例患者可检测到抗中性粒细胞抗体，2例为细胞性S-AIN，骨髓中存在造血抑制性T细胞。治疗前，所有患者均有感染问题。所有患者在开始治疗后7天内均有反应。只要G-CSF维持中性粒细胞计数高于1×10⁹/L，就不会再发生感染。这可以通过每8天使用一次G-CSF来实现。17例患者中有8例仍在使用G-CSF，尽管有5例因副作用改用糖基化形式。尽管G-CSF的总使用经验为47.29患者年，但无一例发生骨质疏松。总之，糖基化和非糖基化G-CSF均可长期有效用于治疗AIN。
